Combination therapy against anti-PD-1-resistant lung cancer (IMAGE)
Caption
Combination therapy against anti-PD-1-resistant lung cancer. A combination of anti-PD-1 antibodies and stimulator of an interferon gene (STING)-loaded lipid nanoparticles (STING-LNP) had the maximum effect in reducing metastases (black regions) on lungs (pink tissue; far right). STING-lipid nanoparticles alone had a better effect (center right) than anti-PD-1 antibodies (center left), which were as effective as the control saline solution (far left; Takashi Nakamura, et al. Journal for ImmunoTherapy of Cancer. July 2, 2021).
Credit
Takashi Nakamura, et al. Journal for ImmunoTherapy of Cancer. July 2, 2021
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC